Literature DB >> 29231672

Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs. Final rule with comment period.

.   

Abstract

This final rule with comment period revises the Medicare hospital outpatient prospective payment system (OPPS) and the Medicare ambulatory surgical center (ASC) payment system for CY 2018 to implement changes arising from our continuing experience with these systems. In this final rule with comment period, we describe the changes to the amounts and factors used to determine the payment rates for Medicare services paid under the OPPS and those paid under the ASC payment system. In addition, this final rule with comment period updates and refines the requirements for the Hospital Outpatient Quality Reporting (OQR) Program and the ASC Quality Reporting (ASCQR) Program.

Entities:  

Year:  2017        PMID: 29231672

Source DB:  PubMed          Journal:  Fed Regist        ISSN: 0097-6326


  5 in total

1.  Diversity of Participants in the 340B Drug Pricing Program for US Hospitals.

Authors:  Sayeh Nikpay; Melinda Buntin; Rena M Conti
Journal:  JAMA Intern Med       Date:  2018-08-01       Impact factor: 21.873

2.  More Clouds Form Over 340B Program: Potential Medicare Cut Underlines Need to Rein In Program.

Authors:  Stephen Barlas
Journal:  P T       Date:  2017-10

3.  CMS Finalizes Drastic 340B Reimbursement Cut for 2018.

Authors:  Stephen Barlas
Journal:  P T       Date:  2018-01

4.  First Reported Series of Outpatient Total Knee Arthroplasty in the Middle East.

Authors:  Muthana M Sartawi; Hafizur Rahman; James M Kohlmann; Brett R Levine
Journal:  Arthroplast Today       Date:  2020-09-15

5.  Association between same day discharge total knee and total hip arthroplasty and risks of cardiac/pulmonary complications and readmission: a population-based observational study.

Authors:  Jiabin Liu; Nabil Elkassabany; Jashvant Poeran; Alejandro Gonzalez Della Valle; David H Kim; Daniel Maalouf; Stavros Memtsoudis
Journal:  BMJ Open       Date:  2019-12-08       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.